The global tissue engineered skin substitute market is projected to grow from USD 2.4 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 3.9%. The rising demand for advanced wound care solutions ...

Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central ...

Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

ProgenaCare's innovative approach to wound care leverages scientific advancements in biomaterials to deliver effective products for a range of wound types, from acute injuries to chronic conditions.

BioStem expects to finalize definitive agreements within 60 days following customary due diligence. The transaction is subject to regulatory approvals and Board consent. BioStem and ProgenaCare will ...

For breast cancer survivors, we shine a light on a crucial aspect of recovery: the management of wounds and scars ...

The challenges created by industry-wide staffing shortages are widespread, creating stress and frustration for patients and ...

Chrysalis BioTherapeutics, Inc., a clinical stage biopharmaceutical company developing Chrysalin as a Medical Countermeasure and for the treatment of Acute Respiratory Distress Syndrome (ARDS), ...